# TB-500 Research: Mechanism, Tissue-Repair Studies, and Safety Signals > TB-500 and thymosin beta-4 research, organized by finding: 1:1 actin sequestration, +61% rat re-epithelialization, cardiac PINCH–ILK–Akt signaling, the tumor/angiogenesis safety signal, and the TB-500 vs BPC-157 comparison. Structure, wound healing, cardiac and neurological models, angiogenesis, the anti-fibrotic record, the safety signals, and the honest gaps — each finding tagged by evidence grade and by whether it used the seven-mer or the full protein. ## How TB-500 works: actin sequestration TB-500 works through the actin-binding motif it inherits from thymosin beta-4. Structural work settled the mechanism: a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, crystallized to 2 Å, showed the peptide forming a 1:1 complex with monomeric G-actin and sequestering it by capping both ends, which prevents the monomer from joining a filament [1]. The WH2 actin-interacting motif — the part present in the LKKTETQ fragment — underlies that binding. Functionally, sequestering G-actin buffers the pool available for filament assembly, which is how the parent protein regulates cytoskeletal dynamics, cell motility and migration [5]. Cell migration is the through-line of almost every downstream effect attributed to thymosin beta-4: keratinocytes resurfacing a wound, endothelial cells building vessels, myoblasts answering an injury signal. The TB-500 heptapeptide is the actin-binding handle of that machinery; the open question is how much of the full protein's signaling the handle alone reproduces in humans. ## TB-500 and full-length thymosin beta-4: the identity distinction The single most important caveat on this site is an identity one. "TB-500" denotes the Ac-LKKTETQ heptapeptide (~889 Da). The endogenous molecule it is carved from — thymosin beta-4 — is a 43-residue protein (~4963 Da, gene TMSB4X, UniProt P62328) that is the body's principal G-actin sequestering peptide [1]. The fragment is residues 17–23 of that protein and its actin-binding core, but it is not the whole molecule. The overwhelming majority of efficacy studies — wound healing, cardiac repair, stroke, anti-fibrotic work — used full-length thymosin beta-4, not the seven-mer [5]. One mechanistic consequence is concrete: full-length thymosin beta-4 can be cleaved at its N-terminus to release Ac-SDKP, a separate peptide with its own anti-fibrotic and angiogenic activity — and Ac-SDKP is generated from the N-terminal region, NOT from the C-terminal-region TB-500 fragment. So a meaningful slice of the parent protein's anti-fibrotic biology is, by sequence, unavailable to TB-500. Throughout this digest, findings that used the full protein are tagged as such, and the seven-mer's human evidence is reported separately — which, for now, is essentially empty [6]. ## Does TB-500 help wound healing? Thymosin beta-4 accelerated wound healing in the cleanest discrete result in this literature. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold in assay [3]. Topical thymosin beta-4 (the clinical-grade ophthalmic formulation RGN-259) also showed corneal-healing and dry-eye benefit in human trials [16]. Those figures are real and reproducible — and they are full-length-protein, mostly animal-model figures. There is no human wound-healing trial of the TB-500 heptapeptide. ## Does TB-500 affect the heart? In mice, thymosin beta-4 formed a complex with PINCH and integrin-linked kinase (ILK) that activated the survival kinase Akt; it promoted cardiac and endothelial cell migration and, after coronary artery ligation, upregulated ILK/Akt, enhanced early myocyte survival and improved cardiac function [2]. A review positions the protein as a multi-faceted tissue-repair stimulator across heart and brain [10]. The record is not uniformly positive, and the digest reports the misses with the hits. Systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, and human cardiac data remain limited [10]. "Improves cardiac function in mice" and "failed in a pig ischemia-reperfusion model" are both true sentences about the same protein. ## Does TB-500 have neuroprotective effects, promote angiogenesis, and grow hair? Three more parent-protein findings round out the studied-effects picture. In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every 3 days) improved neurological function significantly from day 14 through day 56, while 18 mg/kg gave no significant benefit — a non-monotonic dose-response with a modeled optimum near 3.75 mg/kg [4]. Higher was not better. Thymosin beta-4 also promotes endothelial migration and angiogenesis (via VEGF, HIF-1α and Notch signaling in full-length studies) [5], and at nanomolar concentrations stimulated hair growth in rats and mice by activating hair-follicle bulge stem cells [5]. The angiogenesis finding is double-edged and reappears in the safety section: the same pro-migratory, pro-angiogenic activity that aids repair could, in principle, support tumor progression. ## Does TB-500 work for muscle and connective-tissue repair? Muscle-injury signaling recruits thymosin beta-4, which acts as a myoblast chemoattractant [5]. But the cleanest muscle outcome is a cautionary one: in dystrophin-deficient mdx mice, chronic thymosin beta-4 (150 µg twice weekly intraperitoneally for six months) increased the number of regenerating fibers without improving muscle strength, cardiac function or fibrosis [5]. More regeneration on histology did not translate to more function. There are no human muscle-injury efficacy trials of TB-500. ## Reported safety signals and side effects in the research literature TB-500 side effects cannot be quantified from controlled human data, because none exist for the heptapeptide [6]. The honest safety picture is built from two things: the absence of trials, and a specific biological signal. The signal is the tumor and angiogenesis concern. Thymosin beta-4 is overexpressed in several cancers (including pancreatic and colorectal) and is implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. That is a noted, mechanistically grounded concern — not an established human outcome, and not a claim that TB-500 causes cancer. The second issue is material quality: peptide identity, purity and correct sequence (full-length versus fragment) are not guaranteed in unregulated supply, which also complicates interpreting anecdotal results [17]. ## Is TB-500 safe? What the evidence shows Whether TB-500 is safe cannot be answered from controlled human data on the heptapeptide, because there is none [6]. The closest human safety reference is for the full protein: in a randomized, placebo-controlled Phase 1 study, intravenous thymosin beta-4 given to 40 healthy volunteers — single dose then daily for 14 days at 42, 140, 420 or 1260 mg — was well tolerated with only infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events; pharmacokinetics were dose-proportional [6]. That establishes short-term IV tolerability of full-length thymosin beta-4, not the long-term safety of the seven-mer. A 2026 narrative review listing TB-500 and BPC-157 among unapproved peptides concluded that many show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [11]. ## TB-500 compared with BPC-157 in the literature TB-500 and BPC-157 are frequently discussed together and are mechanistically distinct. TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4, acting through actin sequestration [1]. BPC-157 is a separate, gastric-juice-derived peptide with its own proposed mechanisms. They are not the same molecule and do not share a target. What they share is regulatory and evidentiary standing. A 2026 Sports Med review lists both among unapproved peptides with animal-model promise but scarce human safety data, operating largely outside regulatory oversight [11]. Both are placed by the FDA in 503A Category 2, and both are individually named on the published agenda of the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting as substances being considered for the 503A bulks list — a scheduled discussion, not a decision. See the [FDA 503A category and compounding access](/legal-status) page for that detail. --- A depth-layered reading of the TB-500 and thymosin beta-4 record — the seven-mer kept distinct from its full-length parent, the human-trial gap surfaced first, and no clinic, vendor, or prescription anywhere in the void.